Nanoconveyors of drugs in cancer cells are created in Russia

The molecule, capable to deliver drugs in the core of a cell, including affected by cancer process, is developed in Russia, is spoken in the report of the director of Institute of biology of a gene of the Russian Academy of Sciences of academician George Georgiyev and the head of the laboratory of molecular genetics of intracellular transport Alexander Sobolev. Such "supplier" does treatment at least one thousand times more effective in comparison with usual therapy, transfers ITAR-TASS. "As a serious call for those who frames specific and effective remedies of treatment, the paradoxical situation serves. It is at the same time necessary to use so-called superficial molecular markers to provide cellular specificity of medicine whereas achievement of maximum efficiency demands medicine delivery in a cell, in its certain part", - Alexander Sobolev told. For anticancerogenic agents such delivery has to be carried out usually immediately in a core, the scientist specified. But for this purpose it is necessary to frame a certain transport of medicine in the right place, uniting to two inconsistent demand. "We developed the modular nanoconveyors (MNT), allowing to achieve it", - Sobolev noted.

For this purpose from different natural molecules separate modules were taken and bridged in himerny, speaking to words of scientists, artificial protein about 10 nanometers in size. It also is MNT, and all modules keep the functions in its structure. MNT after intravenous administration collect mainly in tumoral cells, and in them – mainly in cores. Besides, these conveyors are a little toxic and almost immunogens. Thanks to it drugs for photodynamic therapy of a cancer – so-called photosensitinogens (FS), – delivered by the nanoconveyor in cancer cells, appear by 1000-3000 times more effective in comparison with free FS. So, for example, therapy of the epidermoid carcinoma of the person inoculated to mice with application of MNT causes an appreciable growth inhibition of a tumor and provides survival of 75% of mice with tumors while usual, free FS yields result only in 20%. Similar results were received and when using other antitumoral preparations. "High efficiency of therapy with application of various MNT allows to raise a question of possibility of application of conveyors of this sort for treatment of malignant neoplasms in clinic", - researchers emphasized. Now preclinical tests of MNT come to the end.